Instructions:

* Read the article on page 416.

* Take the test, recording your answers in the test answers section (Section B) of the CE enrollment form. Each question has only one correct answer.

* Complete registration information (Section A) and course evaluation (Section C).

* Mail completed test with registration fee to: Lippincott Professional Development, CE Group, 74 Brick Blvd., Bldg., 4 Suite 206, Brick, NJ 08723.

* Within 4-6 weeks after your CE enrollment form is received, you will be notified of your test results.

* If you pass, you will receive a certificate of earned contact hours and answer key. If you fail, you have the option of taking the test again at no additional cost.

* A passing score for this test is 7 correct answers.

* Need CE STAT? Visit http://www.nursingcenter.com for immediate results, other CE activities, and your personalized CE planner tool.

* No Internet access? Call 800-787-8985 for other rush service options.

* Questions? Contact Lippincott Professional Development: 800-787-8985

Registration Deadline: December 2, 2022

Provider Accreditation:

Lippincott Professional Development (LPD) will award 1.0 contact hours for this continuing nursing education activity.

LPD is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.0 contact hours. LWW is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida #50-1223.

Disclosure: The author and planners have disclosed no potential conflicts of interest, financial or otherwise.

This article has been approved by the Orthopaedic Nurses Certification Board for Category A credit toward recertification as an ONC.

Payment and Discounts:

* The registration fee for this test is $5.00 for NAON members and $10.00 for nonmembers.

* If you take two or more tests in any nursing journal published by LWW and send in your CE enrollment forms together, you may deduct $0.95 from the price of each test.

* We offer special discounts. Send in 6 tests together and the least expensive one is free; send in 12 tests and the 2 least expensive ones are free, etc. We also offer institutional bulk discounts for multiple tests. Call 800- 787-8985 for more information.

CE TEST QUESTIONS

GENERAL PURPOSE: To provide an overview of nonossifying fibroma (NOF), with a case study.

LEARNING OBJECTIVES/OUTCOMES: After completing this continuing education activity, you should be able to:

1. Specify the incidence and pathophysiology of NOF.

2. Distinguish signs of NOF including related findings on diagnostic imaging.

3. Summarize the clinical management of NOF.

1. Nonossifying fibroma (NOF), sometimes referred to as a fibrous cortical defect, is found in approximately what total percentage of the population?

a. 10%

b. 20%

c. 30%

2. NOF most commonly occurs in the

a. metaphysis of long bones.

b. diaphysis of long bones.

c. long bones of upper extremities.

3. Typically, those diagnosed with NOF present

a. with a history of chronic aching pain.

b. with sharp localized pain and swelling.

c. without symptoms.

4. Most NOFs form during

a. early childhood.

b. the first two decades of life.

c. young adulthood through middle age.

5. In approximately 80% of NOF tumors, there is cell mutation causing activation of

a. PI-3-kinase signaling.

b. an oxidative stress response and Nrf2 alteration.

c. the RAS-MAPK pathway.

6. An unremarkable course for NOF would most typically involve spontaneous resolution

a. during adolescence, within weeks to months of onset.

b. with a residual sclerotic region of bone left in adulthood.

c. without evidence of insult by the time the skeleton reaches maturity.

7. All of the following imaging results are consistent with NOF except

a. well circumscribed, eccentric lesion with low signal on T1 and T2 weighted images

b. interspersed high signal within a focal soft tissue edema pattern

c. eccentric bone lesion with a sclerotic rim and narrow zone of transition

8. Smaller NOF lesions in non-weight bearing bones which are asymptomatic

a. may be monitored with serial imaging.

b. should be biopsied.

c. may respond to non-steroidal anti-inflammatory medication.

9. Larger NOS lesions in weight bearing bones

a. are likely to require surgical intervention.

b. are generally not at high risk for fractures.

c. may respond to osteoclast inhibitors.

10. The best course of action for any patient diagnosed with NOF includes

a. bracing and growth monitoring.

b. long term physical therapy for safe weight bearing.

c. referral to an orthopedic oncologist.